| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $88M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $14,781,163 | 26 | 100 |
| Balachandran Madhavan | director | 0 | $0 | 1 | $30,518 | $-30,518 |
| Jacques Rachelle Suzanne | director | 0 | $0 | 1 | $30,518 | $-30,518 |
| Meek David D. | director | 0 | $0 | 1 | $30,518 | $-30,518 |
| POST LEONARD E | director | 0 | $0 | 1 | $30,518 | $-30,518 |
| Springhorn Jeremy P. | director | 0 | $0 | 1 | $30,518 | $-30,518 |
| Abi-Saab Walid | Chief Medical Officer | 0 | $0 | 3 | $44,244 | $-44,244 |
| Potts Jeannette | Chief Legal Officer | 0 | $0 | 3 | $186,968 | $-186,968 |
| KLEMT CHRISTIAN | Chief Financial Officer | 0 | $0 | 5 | $1.33M | $-1.33M |
| Kaye Jack | director | 0 | $0 | 3 | $1.38M | $-1.38M |
| Gut Robert | director | 0 | $0 | 3 | $1.54M | $-1.54M |
| Kapusta Matthew C | CEO, Managing Director | 0 | $0 | 4 | $10.15M | $-10.15M |
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Over the last 12 months, insiders at uniQure N.V. have bought $0 and sold $14.78M worth of uniQure N.V. stock.
On average, over the past 5 years, insiders at uniQure N.V. have bought $0 and sold $5.04M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-03-04 | Sale | Kapusta Matthew C | CEO, Managing Director | 14,581 0.0237% | $9.06 | $132,104 | +82.30% | |
| 2026-03-04 | Sale | KLEMT CHRISTIAN | Chief Financial Officer | 12,000 0.0195% | $9.06 | $108,720 | +82.30% | |
| 2026-03-04 | Sale | Abi-Saab Walid | Chief Medical Officer | 808 0.0013% | $9.06 | $7,320 | +82.30% | |
| 2026-03-04 | Sale | Potts Jeannette | Chief Legal Officer | 3,412 0.0056% | $9.06 | $30,913 | +82.30% | |
| 2026-03-02 | Sale | Kapusta Matthew C | CEO, Managing Director | 34,437 0.0356% | $9.95 | $342,648 | +52.43% | |
| 2026-03-02 | Sale | KLEMT CHRISTIAN | Chief Financial Officer | 12,532 0.013% | $9.95 | $124,693 | +52.43% | |
| 2026-03-02 | Sale | Abi-Saab Walid | Chief Medical Officer | 1,660 0.0017% | $9.95 | $16,517 | +52.43% | |
| 2026-03-02 | Sale | Potts Jeannette | Chief Legal Officer | 8,578 0.0089% | $9.95 | $85,351 | +52.43% | |
| 2026-02-25 | Sale | Kapusta Matthew C | CEO, Managing Director | 12,378 0.0193% | $23.86 | $295,339 | -31.94% | |
| 2026-02-25 | Sale | KLEMT CHRISTIAN | Chief Financial Officer | 6,217 0.0097% | $23.86 | $148,338 | -31.94% | |
| 2026-01-12 | Sale | Gut Robert | director | 25,613 0.0506% | $24.62 | $630,483 | -1.48% | |
| 2026-01-09 | Sale | Kaye Jack | director | 6,390 0.0127% | $27.28 | $174,319 | -10.07% | |
| 2025-11-06 | Sale | Gut Robert | director | 31,434 0.0231% | $27.26 | $856,881 | -13.91% | |
| 2025-11-04 | Sale | Kaye Jack | director | 38,810 0.0317% | $30.34 | $1.18M | -21.88% | |
| 2025-09-26 | Sale | KLEMT CHRISTIAN | Chief Financial Officer | 15,000 0.0277% | $55.00 | $825,000 | -54.07% | |
| 2025-09-24 | Sale | Kapusta Matthew C | CEO, Managing Director | 226,316 0.36% | $41.46 | $9.38M | -47.31% | |
| 2025-09-24 | Sale | KLEMT CHRISTIAN | Chief Financial Officer | 3,000 0.0046% | $40.04 | $120,120 | -47.31% | |
| 2025-06-27 | Sale | Abi-Saab Walid | Chief Medical Officer | 1,466 0.0027% | $13.92 | $20,407 | +63.28% | |
| 2025-06-20 | Sale | Gut Robert | director | 3,336 0.0062% | $14.45 | $48,205 | +57.14% | |
| 2025-06-20 | Sale | Balachandran Madhavan | director | 2,112 0.0039% | $14.45 | $30,518 | +57.14% |
| Increased Positions | 143 | +52.38% | 24M | +43.23% |
| Decreased Positions | 127 | -46.52% | 17M | -31.45% |
| New Positions | 70 | New | 10M | New |
| Sold Out Positions | 65 | Sold Out | 8M | Sold Out |
| Total Postitions | 289 | +5.86% | 62M | +11.78% |
| Fmr Llc | $141,733.00 | 9.77% | 6.06M | +5M | +411.63% | 2025-09-30 |
| Avoro Capital Advisors Llc | $103,956.00 | 7.17% | 4.44M | +819,444 | +22.61% | 2025-09-30 |
| Rtw Investments, Lp | $103,500.00 | 7.14% | 4.42M | -733,263 | -14.21% | 2025-09-30 |
| Ecor1 Capital, Llc | $93,302.00 | 6.43% | 3.99M | 0 | 0% | 2025-09-30 |
| Aberdeen Group Plc | $68,761.00 | 4.74% | 2.94M | +189,029 | +6.87% | 2025-09-30 |
| Franklin Resources Inc | $46,513.00 | 3.21% | 1.99M | +383,066 | +23.86% | 2025-09-30 |
| Blackrock, Inc. | $33,824.00 | 2.33% | 1.45M | +112,436 | +8.43% | 2025-09-30 |
| State Street Corp | $33,775.00 | 2.33% | 1.44M | +301,200 | +26.36% | 2025-09-30 |
| Fred Alger Management, Llc | $30,182.00 | 2.08% | 1.29M | +1M | New | 2025-09-30 |
| Jpmorgan Chase & Co | $26,883.00 | 1.85% | 1.15M | -658,334 | -36.42% | 2025-09-30 |